Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CDT Equity Inc. - Common Stock (NQ:CDT)

0.8006 -0.3794 (-32.15%)
Streaming Delayed Price Updated: 2:59 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CDT Equity Inc. - Common Stock

< Previous 1 2 Next >
CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
Cryptocurrency treasury reserve strategy is designed to diversify capital structure while reinforcing CDT's innovation-led model 
From CDT Equity Inc.
Via GlobeNewswire
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial data 
From CDT Equity Inc.
Via GlobeNewswire
Conduit to Change Name to CDT Equity Inc.
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Leadership Changes
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Progresses Phase II of its AI Initiative with Sarborg
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value 
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
From Conduit Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.